Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Intercept Pharmaceuticals's Sloan Ratio for the quarter that ended in Mar. 2023 was -13.92%.
As of Mar. 2023, Intercept Pharmaceuticals has a Sloan Ratio of -13.92%, indicating there is a warning stage of accrual build up.
Intercept Pharmaceuticals Sloan Ratio % Historical Data
The historical data trend for Intercept Pharmaceuticals's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Intercept Pharmaceuticals Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Sloan Ratio %
-4.02
10.72
-45.79
-22.98
-2.39
Intercept Pharmaceuticals Quarterly Data
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Sloan Ratio %
-5.35
3.14
-19.48
-2.39
-13.92
Competitive Comparison
For the Biotechnology subindustry, Intercept Pharmaceuticals's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intercept Pharmaceuticals Sloan Ratio % Distribution
For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Intercept Pharmaceuticals's Sloan Ratio % falls in comparison to its industry or sector. The grey bar indicates the Sloan Ratio %'s extreme value range as defined by GuruFocus.
Intercept Pharmaceuticals Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Intercept Pharmaceuticals's Sloan Ratio for the fiscal year that ended in Dec. 2022 is calculated as
Intercept Pharmaceuticals's Net Income for the trailing twelve months (TTM) ended in Mar. 2023 was -7.528 (Jun. 2022 ) + 267.453 (Sep. 2022 ) + -20.825 (Dec. 2022 ) + -32.135 (Mar. 2023 ) = $207.0 Mil.
Intercept Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2023 was 14.738 (Jun. 2022 ) + -16.588 (Sep. 2022 ) + -4.806 (Dec. 2022 ) + -51.597 (Mar. 2023 ) = $-58.3 Mil.
Intercept Pharmaceuticals's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2023 was -0.578 (Jun. 2022 ) + 331.582 (Sep. 2022 ) + -54.935 (Dec. 2022 ) + 59.323 (Mar. 2023 ) = $335.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intercept Pharmaceuticals (NAS:ICPT) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2023, Intercept Pharmaceuticals has a Sloan Ratio of -13.92%, indicating there is a warning stage of accrual build up.
Intercept Pharmaceuticals Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Intercept Pharmaceuticals (NAS:ICPT) Business Description
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Create New Portfolio
Portfolio Contest
Personalize
Premium Gurus 
0.82(7.25%) Volume: 539,284 11:33AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
ICPT has been successfully added to your 
